Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott LaboratoriesXSWX:ABT +1.64%78 Cash-to-Debt is 0.17 as of Jun. 2026, which is 63% below its 10-year median of 0.46. GuruFocus rates XSWX:ABT with a GF Score™ of 78/100 and a GF Value™ of CHF105.37. The stock has 2 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 86.08% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Abbott Laboratories's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.17.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Abbott Laboratoriescouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Abbott Laboratories's Cash-to-Debt or its related term are showing as below:
XSWX:ABT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: 0.46 Max: 0.85
Current: 0.17
During the past 13 years, Abbott Laboratories's highest Cash to Debt Ratio was 0.85. The lowest was 0.16. And the median was 0.46.
XSWX:ABT's Cash-to-Debt is ranked worse than 86.08% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs XSWX:ABT: 0.17
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Abbott Laboratories Cash-to-Debt Related Terms
Abbott Laboratories Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:ABT vs SYK, MDT, BSX: Cash-to-Debt Comparison
For the Medical Devices subindustry, Abbott Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (XSWX:ABT) has a Cash-to-Debt of 0.17 as of Jun. 2026. This is 63% below median its historical median of 0.46. Over the past decade, Abbott Laboratories' Cash-to-Debt has ranged from 0.16 to 0.85. According to the industry distribution chart, Abbott Laboratories ranks #699 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 86.1%.
Is Abbott Laboratories' Cash-to-Debt too high?
Abbott Laboratories' current Cash-to-Debt of 0.17 is 63% below median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 0.85. The Medical Devices & Instruments industry median Cash-to-Debt is 1.68. Abbott Laboratories' value of 0.17 is 89.9% below this industry median. Based on the distribution chart, Abbott Laboratories ranks #699 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Abbott Laboratories has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Cash-to-Debt compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #699 out of 812 companies for Cash-to-Debt. This places Abbott Laboratories in the lower half of its industry. The industry median Cash-to-Debt is 1.68. Abbott Laboratories' value of 0.17 is 89.9% below this benchmark. Historically, Abbott Laboratories' own Cash-to-Debt has ranged from 0.16 to 0.85 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 1.68, Abbott Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.68, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current Cash-to-Debt of 0.17 is 89.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Cash-to-Debt is 0.17, which is 63% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current Cash-to-Debt of 0.17. The stock's GF Value™ is CHF105.37, compared to a current price of CHF93.00 — trading 11.7% below its estimated fair value. The current Cash-to-Debt is 0.17, which is 63% below median its 10-year median of 0.46 and 89.9% below the Medical Devices & Instruments industry median of 1.68. Abbott Laboratories' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current Cash-to-Debt is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF93.00 is trading 11.7% below its estimated GF Value™ of CHF105.37.
Key valuation signals for XSWX:ABT:
Cash-to-Debt: 0.17 (63% below median its 10-year median of 0.46)
GF Value™: CHF105.37 vs. price of CHF93.00 (11.7% below fair value)
Industry Position: 89.9% below the Medical Devices & Instruments median (#699 of 812)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
78GF Score
Get the complete analysis for XSWX:ABT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
